Cash FlowThe company’s present forecasts suggest less than 12 months of cash runway, indicating a likely need to tap the equity markets.
Financial PerformanceEkso Bionics reported revenues of $4.1M, lower than the consensus estimate of $5.5M, and a net loss of $0.10 per share.
Medicare ReimbursementThe entire process of Medicare Part B reimbursement for Indego Personal devices is moving more slowly than anticipated, leading to investor disappointment.